Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PDUFA VI: 'Building Trust' Is Theme Of FDA-Industry Negotiations

Executive Summary

Major achievements of latest drug user fee agreement include focus on drug development cycle, more review time and pilot programs, FDA and industry reps tell DIA meeting.

You may also be interested in...



Best Of Biosimilar Agreement: FDA, Industry Tout Written Response, Pre-Submission Meeting

FDA's Leah Christl and Amgen and Sandoz representatives discuss key achievements of BsUFA II at DIA meeting; Christl expects to see interchangeable biosimilars come to market within the next two years.

Best Of Biosimilar Agreement: FDA, Industry Tout Written Response, Pre-Submission Meeting

FDA's Leah Christl and Amgen and Sandoz representatives discuss key achievements of BsUFA II at DIA meeting; Christl expects to see interchangeable biosimilars come to market within the next two years.

Rejecting PhRMA's Request, US FDA Sticks With Size Over Function In Defining Biologic

Agency's final rule defines protein based on size of amino acid sequence, irrespective of method of manufacture, saying this 'bright-line rule' provides regulatory certainty.

Topics

Related Companies

UsernamePublicRestriction

Register

PS120903

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel